TrialJCI insight2025

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.

David Strawn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.